Profile data is unavailable for this security.
About the company
Nanorepro AG is a Germany-based company active in the biotechnology sector. The Company is engaged in the research of stem cells, which are used in the medical treatment due to their ability to self-renew and differentiate to a range of specialized cell types. Nanorepro AG gathers samples of patients’ stem cells and stores them for the future use. Its portfolio also comprises OTC rapid diagnostic tests, such as OvuQUICK, an ovulation test for women; GraviQUICK, a pregnancy test; MenoQUICK, a menopause test; VagiQUICK, a vaginal yeast test; GlutenCHECK, a test to detect celiac disease; CholesterinCHECK, a test to measure the level of total cholesterol, HDL and LDL, as well as FertiQUICK, a fertility test for men.
- Revenue in EUR (TTM)13.93m
- Net income in EUR-6.58m
- Incorporated2007
- Employees17.00
- LocationNanoRepro AGUntergasse 8MARBURG AN DER LAHN 35037GermanyDEU
- Phone+49 6 421951449
- Fax+49 6 421951451
- Websitehttps://www.nanorepro.com/
Holder | Shares | % Held |
---|---|---|
TBF Global Asset Management GmbHas of 31 Mar 2024 | 813.71k | 6.31% |
SIGNAL IDUNA Asset Management GmbHas of 31 Mar 2024 | 258.00k | 2.00% |
Aramea Asset Management AGas of 31 Mar 2024 | 244.19k | 1.89% |
Discover Capital GmbHas of 30 Jun 2023 | 100.00k | 0.78% |
Axxion SA (Luxembourg)as of 31 May 2024 | 83.74k | 0.65% |